Four Children With Terminal Brain Cancer Are Growing Up After An Experimental Trial Nobody Expected To Work
Diffuse intrinsic pontine glioma, known as DIPG, is a brain cancer that forms in the brainstem of children and is, by almost every measure, one of the most devastating diagnoses in pediatric medicine. Children with DIPG typically survive for less than a year after diagnosis. There are no effective standard treatments. Radiation can buy a small amount of time but does not cure the disease, and dozens of clinical trials over decades have produced nothing that meaningfully extended survival. When researchers at Children's National Hospital in Washington, D.C., launched a Phase 1 trial called ReMIND to test a new immune cell therapy in children with DIPG and other treatment-resistant brain tumors, the primary goal was simply to determine whether the treatment was safe. They were not expecting to see what happened next. The results of the trial, published in Nature Medicine in June 2026, found that four children and young adults who received the therapy are still alive years after treatment, and three of them currently show no evidence of disease. For a cancer that has killed nearly every child it has ever touched, the phrase no evidence of disease is almost without precedent.
The treatment is called tumour-associated antigen T-cell therapy, or TAA T-cell therapy, and it works by collecting a patient's own T-cells, training them in the laboratory to recognize multiple proteins found on the surface of tumor cells, and reinfusing them so the immune system can attack the cancer more effectively. Unlike CAR T-cell therapy, which genetically modifies T-cells, TAA T-cell therapy works with the existing immune machinery, which appears to result in fewer side effects: most patients in the trial experienced only fatigue and headache, and two experienced tumor swelling that may have been related to existing tumor size rather than the therapy itself. The trial enrolled 33 children and young adults, and while most did not respond in the sustained way the four long-term survivors did, the trial accomplished all of its primary safety objectives and established a manufacturing process that is reproducible at clinical scale, a critical bottleneck that has slowed cell therapies in the past. Gene Hwang, a member of the research team at Children's National Hospital, offered a summary of the four surviving children that required no elaboration: these children are getting to grow up. It's truly awesome.
